CASE REPORT
Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin

https://doi.org/10.1016/S1081-1206(10)61714-0Get rights and content

Background

In some patients with Churg-Strauss syndrome (CSS), especially those with myocardial or neural involvement, conventional treatment with corticosteroids with or without cyclophosphamide is not effective.

Objective

To examine the effects of intravenous high-dose immunoglobulin (IVIG) in patients with CSS who showed poor responsiveness to conventional treatment.

Methods

We consecutively selected patients with CSS who showed any organ involvement despite corticosteroid treatment with or without cyclophosphamide. The diagnosis was based on the classification criteria of the American College of Rheumatology. IVIG therapy was performed with a dose of 400 mg/kg of immunoglobulin daily for 5 days. Neuropathy was evaluated with the manual muscle strength test and by the skin temperature of affected sites. Cardiac function was examined with ejection fraction by echocardiography and 2 imaging tests of myocardium (iodine 123 metaiodobenzylguanidine and thallium 201).

Results

The manual muscle strength test results were improved, and the skin temperature of both hands and legs was increased by IVIG therapy. In 5 patients with heart failure, the mean ± sd ejection fraction of the left ventricle increased from 35.2% ± 13.9% to 61.0% ± 10.1% (P < .02). The uptake of iodine 123 metaiodobenzylguanidine of the myocardium increased, indicating that the myocardial viability was improved. The thallium 201 images revealed the presence of perfusion defects, which were improved by IVIG therapy.

Conclusions

Patients with CSS who are resistant to corticosteroid treatment with or without cyclophosphamide may be treated effectively with IVIG therapy.

REFERENCES (38)

  • M Gayraud et al.

    Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients

    Arthritis Rheum.

    (2001)
  • N Hattori et al.

    Clinicopathological features of Churg-Strauss syndrome-associated neuropathy

    Brain.

    (1999)
  • E Renaldini et al.

    Cardiac involvement in Churg-Strauss syndrome: a follow-up of three cases

    Eur Heart J.

    (1993)
  • L Guillevin et al.

    Churg-Strauss syndrome: clinical study and long-term follow-up of 96 patients

    Medicine.

    (1999)
  • RP Kleyweg et al.

    Treatment of Guillain-Barre syndrome with high-dose gammaglobulin

    Neurology.

    (1988)
  • JM Faed et al.

    High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy

    Neurology.

    (1989)
  • JP Azulay et al.

    Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study

    Neurology.

    (1994)
  • CM Lockwood

    New treatment strategies for systemic vasculitis: the role of intravenous immune globulin therapy

    Clin Exp Immunol.

    (1996)
  • A Armentia et al.

    Asthma and vasculitis: response to intravenous immunoglobulins

    Allergol Immunopathol.

    (1993)
  • Cited by (115)

    • Intravenous Immunoglobulin: Mechanism of Action in Autoimmune and Inflammatory Conditions

      2023, Journal of Allergy and Clinical Immunology: In Practice
    • Treatment and Management of Autoimmune Neuropathies

      2021, Neuromuscular Disorders: Treatment and Management
    • ANCA associated vasculitis

      2020, European Journal of Internal Medicine
    View all citing articles on Scopus
    View full text